Immunoglobulin News and Research

RSS

How durable is the immune response generated from the BNT162b2 vaccine?

In a recent study, researchers analyzed antibody responses to the homologous Wu strain and several other SARS-CoV-2 variants after BNT162b2 vaccination.

4 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

A recent study by a multidisciplinary team of cardiologists and infectious disease specialists at Children's Hospital Colorado (Children's Colorado) found that pediatric patients suffering from Multisystem Inflammatory Syndrome (MIS-C) who received initial, intensified therapy consisting of intravenous immunoglobulin (IVIG) plus Infliximab had improved cardiac outcomes versus those who received IVIG alone.

30 Sep 2021

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

A new study aimed to determine the course of SARS-CoV-2 infection in children suffering from rheumatic disease and were receiving bDMARD treatment.

29 Sep 2021

Vaccine-induced SARS-CoV2 immune responses decline at similar rates as those after infection, study finds

A new preprint describes the causal role of waning antibody titers in decreased antibody persistence at one year.

29 Sep 2021

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A new study discusses the development of dedicated reagents against the SARS-CoV-2 spike protein through the use of an automated CLEIA system.

28 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

New research discusses the development of soluble prefusion-stabilized spike trimers (CoV2 preS dTM) comprising adjuvant AS03.

27 Sep 2021

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

A team from the National Institute for Infectious Diseases “L. Spallanzani” (INMI) has recently reported their study on 94 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (47.9% symptomatic, 52.1% asymptomatic) that occurred after the first or second vaccine dose against SARS-CoV-2 in the Lazio region (Central Italy).

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

Natural infection or vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confer considerable protection against reinfection and reduce the risk of severe Coronavirus disease 2019 (COVID-19) outcomes.

24 Sep 2021

How SARS-CoV-2 spike binds to multiple host receptors

Researchers from the Genos Glycoscience Research Laboratory in Croatia have recently investigated the sites that the S protein is capable of binding with.

23 Sep 2021

COVID-19 vaccination and lactation

A new study evaluates the presence of antibodies in breastmilk and the immune responses of lactating women after vaccination of the COVID-19 vaccine.

23 Sep 2021

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

A new preprint describes the significant variation in the early immune response elicited by two of the earliest vaccines to gain emergency authorization against COVID-19.

23 Sep 2021

Differences in blood gene expression among patients with varying COVID-19 severity

A new study published on the medRxiv* pre-print server and currently undergoing peer-review aims to answer this question through whole blood transcriptomics of individuals with varying degrees of COVID-19 severity. Transcriptomics, done by RNA sequencing, gives insights into the genes expressed in a cell at a given time point. It gives an analysis of all RNA molecules within a cell, in this case, whole blood.

23 Sep 2021

Immunoglobulin News and Research

How durable is the immune response generated from the BNT162b2 vaccine?

Using a new public antibody to understand SARS-CoV-2 neutralization

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

Vaccine-induced SARS-CoV2 immune responses decline at similar rates as those after infection, study finds

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Chronic COVID-19 and divergent variants of SARS-CoV-2

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

How SARS-CoV-2 spike binds to multiple host receptors

COVID-19 vaccination and lactation

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

Differences in blood gene expression among patients with varying COVID-19 severity

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Comparison of recombinant SARS-CoV-2 receptor binding domain produced in mammalian, insect, and bacterial cells

COVID-19 induces the generation of distinct autoantibodies

Three US COVID-19 vaccines provide substantial protection against hospitalization

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News